MPL – Morgan Stanley rates the stock as Underweight

By Broker News | More Articles by Broker News

Morgan Stanley suspects a 2% cap on premium increases in 2020 and 2021 is a most likely outcome for private health insurers. Private health has emerged as a key policy debate in the upcoming federal election.

The broker suspects the industry will underperform again in 2019, despite multiples de-rating to substantially below historical averages.

Regulated profit pools make up around 90% of Medibank Private’s earnings and, the broker notes, the ADF contract loss is a major blow to the company’s ambitions to double non-insurance earnings.

Target is reduced to $2.15 from $2.30. Underweight rating maintained.  Industry view: In-Line.

Sector: Insurance.

Target price is $2.15.Current Price is $2.62. Difference: ($0.47) – (brackets indicate current price is over target). If MPL meets the Morgan Stanley target it will return approximately -22% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →